spacer
home > ebr > autumn 2017 > new strategy
PUBLICATIONS
European Biopharmaceutical Review

New Strategy

To move away from ‘all-comers’ trials, the early identification of genetic factors influencing effectiveness in patient subpopulations is key. A recent increase in the use of predictive human tissue models led to the idea for a nationwide multidisciplinary collaboration that combined assays in fresh, diseased human tissues studied ex vivo, with whole exome sequencing. This allowed genomic markers to be recognised, distinguishing patients identified by the human tissue assays as ‘good’ or ‘poor’ responders.

This Scottish pharmacogenomics project has made great strides in the understanding of chronic obstructive pulmonary disease (COPD) and inflammatory bowel diseases (IBD) by using whole exome sequencing, bioinformatics and fresh human tissue assays to relate drug response to genotype. The study findings underpin a new framework for patient stratification in clinical trials that combines in vitro and molecular informatics to improve pharma success rates and accelerate the availability of effective medications.

The most common cause of drug failure is poor efficacy at Phase 1 or 3, which is, in part, attributed to clinical trials of entire patient populations, including both ‘responders’ and ‘nonresponders’ (1,2). Precision medicine can improve the prediction of clinical efficacy by selecting only those patient subpopulations likely to gain clear benefit for trials, but such forecasts require methods to identify patient subpopulations at an early stage, ideally during preclinical testing (2-4). Human tissue data generated in early discovery via a wide range of models – including stem cells, fresh human tissues and pathological specimens – is increasingly being used in preclinical testing (5-7). Tissue samples collected from the target patient population allow researchers to directly test the effect of new drugs in systems that closely reflect the in vivo situation, providing an early prediction of efficacy. The responses of tissues from different patients when studied in vitro can vary considerably, reflecting the clinical reality of responders and non-responders.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
David Bunton is Chief Executive Officer of ReproCELL Europe. He is an experienced and respected human tissue pharmacologist and co-founder of Biopta, which merged with Reinnervate Ltd in July 2016 to form ReproCELL Europe.

Marian McNeil is Business Development Manager at Stratified Medicine Scotland – Innovation Centre. She has recently gained a master's degree in stratified medicine and pharmacological innovation from the University of Glasgow, Scotland, and has extensive experience in the medical marketing interface for oncology pipeline products.

Pamela Brankin joined Aridhia in 2011, taking on the role of Head of Marketing and Communications in 2015. She holds a BA Hons in English and French from the University of Dundee, UK, a postgraduate diploma in information technology from the University of St Andrews, UK, and an advanced diploma in professional French from the Chambre de Commerce et d'Industrie de Paris, France.

spacer
David Bunton
spacer
spacer
spacer
Marian McNeil
spacer
spacer
spacer
Pamela Brankin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Positive results from first preclinical in-vivo studies of Affimer therapeutics


More info >>

White Papers

Working Towards a Standardised Identification Solution

PCI Pharma Services

The security of the pharmaceutical supply chain is an issue of growing concern, with recent reports addressing its vulnerability to counterfeiting. The complexity of the European supply chain is one of the key factors of this counterfeiting pandemic, with millions of medicine packs being moved around the EU, annually. Aside from this, fragmentation has resulted in decreased transparency in the supply chain and increased difficulties to track and trace medicines, leading to significant threat from counterfeiting. As a key source of income for the European economy, it is essential that the supply chain remains safe and free of counterfeits. A significant stumbling block within the industry remains to be the lack of a unified, single‐source pan‐European or indeed global database where scanned bar codes on drug packaging can be verified at point of dispense. At some point in the future the pharmaceutical industry, regulatory bodies, clinicians and retailers will need to join forces to overcome this.
More info >>

 
Industry Events

Global Bioproduction Summit, 5th-6th February 2018

5-6 February 2018, Hilton San Diego Resort & Spa, CA

After 15 years in Europe, the Global Bioproduction Summit moved to its new home of San Diego in 2016. The Bioproduction Summit delves deep into the world of biological production.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement